GEN Exclusives

More »

GEN News Highlights

More »
Jan 16, 2007

Neurobiological Technologies Collects $4M for Xerecept Rights

  • Neurobiological Technologies (NTI)  received $4 million from Celtic Pharmaceutical  as the final noncontingent payment for worldwide rights to Celtic Pharma for Xerecept®, a Phase III clinical compound being studied for the treatment of peritumoral brain edema.

    With this final payment, NTI will have received a total of $33 million in guaranteed payments for the sale of Xerecept. NTI will also receive up to $15 million in additional payments if Xerecept meets certain regulatory milestones. NTI is serving as the CRO for the Phase III Xerecept trials and will receive a share of profits in the U.S. and royalties in other international markets if Xerecept ultimately receives regulatory approval and is commercialized.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?